Oxford Immunotec Global PLC (NASDAQ:OXFD) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

Several other research analysts also recently commented on OXFD. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Cowen and Company reaffirmed a “buy” rating and issued a $22.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Zacks Investment Research downgraded shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, BTIG Research initiated coverage on shares of Oxford Immunotec Global PLC in a research note on Thursday, September 28th. They issued a “buy” rating and a $21.00 target price on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Oxford Immunotec Global PLC presently has an average rating of “Hold” and a consensus price target of $19.67.

Oxford Immunotec Global PLC (OXFD) traded down 15.69% during midday trading on Tuesday, hitting $13.22. 689,196 shares of the stock traded hands. Oxford Immunotec Global PLC has a 52 week low of $11.88 and a 52 week high of $19.51. The stock’s 50-day moving average price is $16.16 and its 200 day moving average price is $15.73. The company’s market capitalization is $305.06 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its earnings results on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, hitting the consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. The company had revenue of $26.10 million for the quarter, compared to the consensus estimate of $25.05 million. During the same period in the previous year, the firm earned ($0.29) earnings per share. The firm’s revenue for the quarter was up 35.9% on a year-over-year basis. On average, equities research analysts predict that Oxford Immunotec Global PLC will post ($1.61) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Downgrades Oxford Immunotec Global PLC (OXFD) to Sell” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/31/valuengine-downgrades-oxford-immunotec-global-plc-oxfd-to-sell.html.

In other Oxford Immunotec Global PLC news, COO Peter Edwardson sold 22,371 shares of the business’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $17.70, for a total transaction of $395,966.70. Following the transaction, the chief operating officer now directly owns 102,644 shares of the company’s stock, valued at approximately $1,816,798.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $15.82, for a total transaction of $47,460.00. Following the transaction, the director now directly owns 18,000 shares in the company, valued at $284,760. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,110 shares of company stock worth $1,523,514. 8.11% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of the business. Wasatch Advisors Inc. increased its position in Oxford Immunotec Global PLC by 34.3% during the 2nd quarter. Wasatch Advisors Inc. now owns 423,831 shares of the company’s stock valued at $7,129,000 after purchasing an additional 108,154 shares during the period. Asymmetry Capital Management L.P. purchased a new position in Oxford Immunotec Global PLC during the 2nd quarter valued at $273,000. The Manufacturers Life Insurance Company increased its position in Oxford Immunotec Global PLC by 8.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock valued at $313,000 after purchasing an additional 1,500 shares during the period. Redmile Group LLC increased its position in Oxford Immunotec Global PLC by 7.5% during the 2nd quarter. Redmile Group LLC now owns 2,155,949 shares of the company’s stock valued at $36,263,000 after purchasing an additional 151,100 shares during the period. Finally, State Street Corp increased its position in Oxford Immunotec Global PLC by 12.4% during the 2nd quarter. State Street Corp now owns 447,104 shares of the company’s stock valued at $7,523,000 after purchasing an additional 49,274 shares during the period. 79.21% of the stock is currently owned by institutional investors and hedge funds.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.